STAT
AUGUST 3, 2024
First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
PharmaTech
AUGUST 3, 2024
Potential conflicts of interest with advisory group members have led to EMA’s impartiality coming into questioned for some marketing authorization decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
AUGUST 3, 2024
In addition to a rapid deterioration, psychosis in Alzheimer disease can also lead to poorer quality of life, damaging patients’ relationships with caregivers, and increases isolation.
PharmaTech
AUGUST 3, 2024
Will Sanofi’s plan to recruit the younger generation through its participation in the upcoming 2024 Olympic and Paralympic Games, being held in Paris, pay off?
Speaker: Jennifer Hill
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Pharmacy Times
AUGUST 3, 2024
Investigators determine the efficacy and safety of the combination in a 2-phase trial.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Drug Patent Watch
AUGUST 3, 2024
This chart shows the pharmaceutical companies with the most patents in Eurasian Patent Organization.
PharmaTech
AUGUST 3, 2024
This acquisition gives AbbVie clinical-stage assets from Cerevel’s pipeline that complement AbbVie's emerging neuroscience pipeline and branded products for treating psychiatric disorders, migraine, and Parkinson's disease.
Drug Patent Watch
AUGUST 3, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim a
Expert insights. Personalized for you.
259 
Let's personalize your content